ERBB2 and ductal breast carcinoma in situ: Previous studies have noted a higher proportion of Her2-positive DCIS cases compared with that seen in invasive disease, and it has previously been suggested that a Her2 DCIS may actually be less likely to progress to IDC60, our findings here would support this hypothesis.